We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Reneuron Group Plc | LSE:RENE | London | Ordinary Share | GB00BF5G6K95 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.05 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 530k | -5.41M | -0.0946 | -0.32 | 1.74M |
Date | Subject | Author | Discuss |
---|---|---|---|
29/6/2017 09:54 | Any thoughts on results today? Missed the presentation too ;-( D | dennisbergkamp | |
28/6/2017 17:22 | I know good after bad etc. | yachtmaster2 | |
28/6/2017 17:21 | I bought a lot for a very small amount of money yesterday afternoon. Went through as a sell | yachtmaster2 | |
28/6/2017 16:44 | ReNeuron CFO Michael Hunt will be presenting to investors at the Proactive One2One Forum on the evening of 13th July in London. For details and registration, click here: | aim_trader | |
26/6/2017 13:45 | Just bought a few at 1.799 pence at 13.35 for those interested to see if it later indicated it was a buy or a sell.I see plenty of potential upside medium term at this price.Here's to us Freddie and our pension fund. "Per Ardua Ad Astra" and chocks away! Edit: appears to be indicated as a sell on all the share platforms I looked at just now. | algernon2 | |
19/6/2017 19:36 | Another piece of the jigsaw.I doubt it'll be catalyst for a sustained rise in the share price ....more likely to see it meander at 2p for while | audigger | |
19/6/2017 10:27 | Huge potential here, but the market has been bitten to many times by jam tomorrow AIM companies. Although RENE have cash now, its not enough to take these therapies through to commercialisation, even if they do get approval. That's the problem with the share price. I'll continue on the side lines for the time being GLA. | johnb5 | |
19/6/2017 09:47 | FDA Approval is huge. Healthcare in the US is a huge business as its mainly private and paid out for through the huge insurance premiums they have to pay. This really should be flying / taken out by a bigger player. D. | dennisbergkamp | |
19/6/2017 09:30 | It looks like everyone's on early hols across the entire market. Sleepy volumes everywhere. | small crow | |
19/6/2017 09:20 | FDA Approval for their hRPC ophthamology formulation and still not much activity... Incredible! | dennisbergkamp | |
16/6/2017 11:34 | Interesting news today that NHS has made a deal with Roche in order to bring very expensive cancer treatment into hospitals at undisclosed cost/dose. Lets hope it's the beginning of the beginning. | fredd1eboy | |
16/6/2017 11:13 | All very depressing here..........need results to give impetus | chrisdgb | |
16/6/2017 09:21 | Probably my fault as not used to advfn site. Will try to post on this one in future so long as I get replies from time to time. Best wishes. Freddie | fredd1eboy | |
16/6/2017 08:58 | So many new threads . end up unused. This is the thread with the record | norbus | |
15/6/2017 18:04 | Time.........Trade.. 09:02:08...1.8125... | fredd1eboy | |
14/6/2017 08:53 | Why would they sell (BoD)if there is the potential for significant upside? Whilst I don't pretend to understand the post placing fall, I also don't understand why the share price would be expected to be much higher at this stage. At some point people will buy in to the potential but clearly we ain't there yet. | audigger | |
14/6/2017 08:47 | PIs deserve a lot more, having their savings de-risk the company for years ; sadly history with Chris Evans leaves a question mark. About 12 years ago, HM ER subscribed for shares at £2 and was taken out for pennies. | norbus | |
13/6/2017 22:59 | How cheap is cheap? | alimo | |
13/6/2017 09:55 | Looking more and more like being set up for a cheap takeout | norbus | |
12/6/2017 13:02 | No academics them, but pocket liners | norbus | |
10/6/2017 08:21 | Nor - couldn't agree more - these guy's (Bod) don't seem to understand the importance of the small investors. - With grants, seminars, and high flying dinners with large scale investors, they live in a la la world. We Pi's are just as much of the project as them and should be kept more informed! - Ignorant academics! | deutsch3 | |
09/6/2017 10:52 | Incredible share action; There has to be a desperate seller who had enough. Reneuron must surely know the selling camp. I do not understand why the company does not explain a price less than 40% of the major placing they had, when the company is said to have advanced its progress and added value. | norbus | |
08/6/2017 15:41 | Cheers Verger. Best wishes. Fred | fredd1eboy |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions